The FDA has approved a fixed-duration, all-oral regimen of acalabrutinib plus venetoclax for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results